Internal Medicine, Cardiovascular Disease · Palos Park, IL
NPI
1932163037
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
4
Medicare group memberships
Hospitals
5
Hospital affiliations
13011 S 104th Ave Ste 100
Palos Park, IL, 60464
Phone (708) 274-3278
Groups this clinician bills Medicare through
Medicare paid, 2024
$570K
8,577 services
Medicare patients, 2024
3,708
Average age 77
Drug cost, 2024
$829K
4,647 prescriptions
Company payments, 2025
$216
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas T Kason was code 93010 (electrocardiogram), 2,238 times for 1,794 patients. In total Thomas T Kason billed 8,577 services in 62 codes, and Medicare paid $570K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-06-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 93010 Electrocardiogram | Facility | 2,238 | 1,794 | $6.46 | $14K |
| 99232 Hospital E&M - Subsequent | Facility | 1,732 | 803 | $63.33 | $110K |
| 99214 Office E&M - Established | Office | 638 | 369 | $92.21 | $59K |
| 99222 Hospital E&M - Initial | Facility | 609 | 564 | $104.77 | $64K |
| 93306 Echocardiography (TTE/TEE) | Facility | 453 | 445 | $51.72 | $23K |
| J2785 Injection, regadenoson, 0.1 mg | Office | 452 | 112 | $4.94 | $2,235 |
| 85610 Clinical Chemistry | Office | 195 | 81 | $4.20 | $819 |
| 93793 Care Management/Coordination | Office | 195 | 82 | $7.30 | $1,424 |
| A9555 Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 159 | 80 | $416.32 | $66K |
| 80061 Clinical Chemistry | Office | 150 | 125 | $13.12 | $1,968 |
| 99212 Office E&M - Established | Office | 148 | 123 | $39.97 | $5,916 |
| 93015 Electrocardiogram | Office | 134 | 133 | $54.88 | $7,353 |
| 93016 Electrocardiogram | Facility | 133 | 133 | $15.74 | $2,093 |
| 93018 Electrocardiogram | Facility | 132 | 132 | $10.47 | $1,383 |
| 78452 Myocardial Perfusion Scan | Facility | 126 | 126 | $57.69 | $7,269 |
By year: 2022 $727K for 9,210 services; 2023 $778K for 8,706 services; 2024 $570K for 8,577 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 195 | 81 | $4.20 | $819 |
| 80061 Clinical Chemistry | 150 | 125 | $13.12 | $1,968 |
Medicare prescription drug claims, 2024
In 2024, the drug Thomas T Kason prescribed most often to Medicare patients was Rosuvastatin Calcium, with 497 prescriptions and refills. In total Thomas T Kason wrote 4,647 Medicare prescriptions that cost $829K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 497 | 1,438 | 145 | $7,658 |
| Metoprolol Succinate Generic | 459 | 1,294 | 145 | $6,887 |
| Amlodipine Besylate Generic | 405 | 1,112 | 149 | $3,324 |
| Eliquis Apixaban | 357 | 905 | 117 | $519K |
| Atorvastatin Calcium Generic | 302 | 864 | 108 | $3,103 |
| Losartan Potassium Generic | 240 | 660 | 83 | $3,124 |
| Metoprolol Tartrate Generic | 190 | 502 | 71 | $1,770 |
| Lisinopril Generic | 148 | 416 | 52 | $1,742 |
| Potassium Chloride Generic | 125 | 278 | 55 | $1,859 |
| Carvedilol Generic | 122 | 314 | 51 | $1,423 |
| Hydrochlorothiazide Generic | 108 | 304 | 42 | $507 |
| Olmesartan Medoxomil Generic | 102 | 272 | 30 | $1,676 |
| Spironolactone Generic | 101 | 274 | 35 | $1,012 |
| Clopidogrel Clopidogrel Bisulfate | 100 | 284 | 41 | $1,236 |
| Furosemide Generic | 97 | 251 | 45 | $670 |
Brand drugs: - claims; generic drugs: 4,074 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas T Kason $216 ($216 in general payments such as food, travel and fees) from 7 companies. The largest payer was Novartis Pharmaceuticals Corporation with $79.49.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.